Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

pjinvestmentco Jun. 23 at 12:36 PM

$SCYX all time low coming this week most likely 65 cents

0 · Reply

pjinvestmentco Jun. 20 at 9:04 PM

$SCYX 65 cents coming next week

0 · Reply

Pommy1 Jun. 18 at 3:59 PM

$SCYX is this still in mkt.i will follow this as i have sole 95 percent at big loss.now i want to see the co fall which was build on fake news.david as u have destroyed people money n made some good balance in ur account.

1 · Reply

pjinvestmentco Jun. 17 at 9:14 PM

$SCYX I would force GSK to decide on first right of refusal on SCY-247. Scynexis has the right to force GSK to make an offer if they want the drug. I believe GSK will refuse and maybe give back Brexafemme rights for pennies on the dollar to Scynexis

1 · Reply

pantarei Jun. 17 at 9:12 PM

$SCYX definitely dead. What a sad end for a sad sad story... This will be studied in next year: how to going bankrupt deapite a good drug thanks to the worst management ever. Period.

1 · Reply

SnapCrackleStop Jun. 17 at 6:12 PM

$SCYX Expecting some progress on MARIO and $GSK. Company obvious the deadline to restart the trial. Waiting on $GSK to pay or …. What??? $$$

0 · Reply

whob007 Jun. 16 at 7:12 PM

$SCYX This company needs a real CEO with experience, not a DR who clealry has no business managing a public company. I am not saying he does not belong with company certainly at Cheif Medical Officer, but absolutely NOT a CEO which is clear in the direction this stock is headed, The BOD needs to do what they are supposed to do and that is protect shareholders, he needs to be removed and replaced with a true CEO

2 · Reply

whob007 Jun. 16 at 7:11 PM

$SCYX This is one of the most disappointing stocks, and most of it is poor management, especially in sustaining Shareholder value. Lack of transparency and communication with their partners and shareholders is sad.

0 · Reply

Pommy1 Jun. 16 at 2:28 PM

$SCYX just cant wait to hear the news of delisting

0 · Reply

Joe401 Jun. 14 at 11:12 PM

$SCYX this will be a 5 dollar stick year end boys. You heard it here first

1 · Reply

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 3 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 8 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 9 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 9 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 10 months ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 11 months ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 11 months ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 1 year ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 1 year ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 1 year ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 1 year ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 1 year ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 15, 2023, 1:15 PM EST - 1 year ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 13, 2023, 5:17 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 24, 2023, 8:00 AM EDT - 1 year ago

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Oct 6, 2023, 5:20 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

pjinvestmentco Jun. 23 at 12:36 PM

$SCYX all time low coming this week most likely 65 cents

0 · Reply

pjinvestmentco Jun. 20 at 9:04 PM

$SCYX 65 cents coming next week

0 · Reply

Pommy1 Jun. 18 at 3:59 PM

1 · Reply

pjinvestmentco Jun. 17 at 9:14 PM

1 · Reply

pantarei Jun. 17 at 9:12 PM

$SCYX definitely dead. What a sad end for a sad sad story... This will be studied in next year: how to going bankrupt deapite a good drug thanks to the worst management ever. Period.

1 · Reply

SnapCrackleStop Jun. 17 at 6:12 PM

$SCYX Expecting some progress on MARIO and $GSK. Company obvious the deadline to restart the trial. Waiting on $GSK to pay or …. What??? $$$

0 · Reply

whob007 Jun. 16 at 7:12 PM

2 · Reply

whob007 Jun. 16 at 7:11 PM

0 · Reply

Pommy1 Jun. 16 at 2:28 PM

$SCYX just cant wait to hear the news of delisting

0 · Reply

Joe401 Jun. 14 at 11:12 PM

$SCYX this will be a 5 dollar stick year end boys. You heard it here first

1 · Reply

Pommy1 Jun. 13 at 1:23 PM

$SCYX almost time for delisting

0 · Reply

pantarei Jun. 12 at 9:22 PM

$SCYX

0 · Reply

pjinvestmentco Jun. 12 at 8:40 PM

$SCYX If GSK resolution takes 6 months or more Scynexis will need to raise money by 1st qtr 2026

1 · Reply

pjinvestmentco Jun. 12 at 6:40 PM

$SCYX 65 cents coming

0 · Reply

Pommy1 Jun. 12 at 12:55 PM

$SCYX i would loce to see this co delisted n david in jail.

0 · Reply

stocks_up1 Jun. 11 at 4:15 PM

$SCYX - It looks like the annual shareholders meeting is June 25th. Has anyone received a list of items that we are voting on? New board - lol? I usually get something from Fidelity, but have not seem anything come across as of yet. I think they typically mail sobering out as well with a control number to vote. I went to the SCYX website and cannot find anyone there either. That’s less than two (2) weeks away. Are they trying to work out a sale? One can only hope. 🤞

5 · Reply

btm811 Jun. 10 at 2:39 PM

$SCYX this has been under a dollar for well over a month, how much longer till delisting?

1 · Reply

SeekingapeacefulpathMill Jun. 10 at 10:16 AM

$SCYX Just a little bit of a 2021 article that shows the potential of our medicine brexafemme the blockbuster drug with the extra 5 years of US exclusivity and you want to what shelve it ? the Fk ? We also have more cash than market cap and Im sure Mario is not costing a ton to run 😎☀️👏 Post something with a celeb and get on a marketing plan . I can wait but you will pay more because I do feel just a little double crossed by both of you ! My girls wouldn't do me like that 😉😆

2 · Reply

pjinvestmentco Jun. 9 at 9:13 PM

$SCYX Scynexis does not control the direction of the stock anymore thanks to David and the Board its now in control of the pump and dump traders.

1 · Reply

pjinvestmentco Jun. 9 at 9:12 PM

$SCYX The company's stock is in control by the pump and dump traders they will manipulate the stock to there advantage but one day it will shoot up to $3 from a big pump day and everyone jump out of at least half then will crash back down under $1 in 3 days

0 · Reply

pantarei Jun. 9 at 6:19 PM

$SCYX full steam towards bankrupt. Shame! Where's brexafemme sales????? Are we waiting for two more years???

0 · Reply

pantarei Jun. 9 at 5:36 PM

$SCYX what a huge pos, symbol of failure and ineptitude!

0 · Reply

Market Cap	28.65M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	46,117
Avg Vol	140,174
Day's Range	N/A - N/A
Shares Out	39.02M
Stochastic %K	2%
Beta	1.65
Analysts	Strong Sell
Price Target	$5.33